Influenza vaccine supplier Seqirus revealed on Tuesday the receipt of approval from the US Food and Drug Administration (FDA) for AFLURIA QUADRIVALENT (Influenza Vaccine) for use in people six months of age and older as well as the trivalent formulation of AFLURIA (Influenza Vaccine).
Influenza is a common, highly contagious infectious disease that can cause severe illness and life-threatening complications in many people. To reduce the risk of more serious influenza-related outcomes, such as hospitalisation and death, the CDC encourages annual vaccination for all individuals aged 6 months and older.
Following the US FDA approval, the AFLURIA QUADRIVALENT is available in the US in pre-filled syringes as well as multi-dose vials for the 2018-2019 influenza season, according to the company.
In August 2016, the AFLURIA QUADRIVALENT was first approved in the US for adults aged 18 years and above and helps protect against two influenza A strain viruses and two B strain viruses, added the company.
Additionally, the AFLURIA (Influenza Vaccine) is a trivalent influenza vaccine developed with egg-based technologies and is indicated for persons aged five or older. It is available in both prefilled syringes and multi-dose vials to provide choice and convenience to patients and caregivers who administer it. It is the only trivalent flu vaccine with a needle-free delivery option for persons 18 through 64 years of age, concluded the company.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial